Barbara Burrall

Metastatic melanoma – A review of current and future treatment options

Despite advances in treatment and surveillance, melanoma continues to claim approximately 9,000 lives in the US annually (SEER 2013). The National Comprehensive Cancer Network currently recommends ipilumumab, vemurafenib, dabrafenib, and high-dose IL-2 as first line agents for Stage IV melanoma. Little data exists to guide management of cutaneous and subcutaneous metastases despite the fact that they are relatively common. Existing options include intralesional Bacillus Calmette-Guérin, isolated limb perfusion/infusion, interferon-α, topical imiquimod, cryotherapy, radiation therapy, interferon therapy, and intratumoral interleukin-2 injections. Newly emerging treatments include the anti-programmed cell death 1 receptor agents (nivolumab and pembrolizumab), anti-programmed death-ligand 1 agents, and oncolytic vaccines (talimogene laherparepevec). Available treatments for select sites include adoptive T cell therapies and dendritic cell vaccines. In addition to reviewing the above agents and their mechanisms of action, this review will also focus on combination therapy as these strategies have shown promising results in clinical trials for metastatic melanoma treatment.

Pancreatic acinar cell carcinoma–induced panniculitis

ACC: acinar cell carcinoma P ancreatic cancer is the fourth most common cause of cancer-related death among men and women in the United States. Every year, an estimated 43,090 people die of pancreatic cancer nationally. Pancreatic acinar cell carcinoma (ACC) is a rare form of pancreatic cancer that accounts for 1% to 2% of all pancreatic neoplasms. ACCs are generally asymptomatic and may be discovered incidentally when patients undergo work-up for general complaints such as abdominal pain. In the literature, investigators have reported a variety of systemic presentations of ACC. Herein, we report a patient with painful lower extremity nodules associated with pancreatic ACC.

Open Access Medical Journals: Benefits and challenges

The world of medical science literature is ever increasingly accessible via the Internet. Open access online medical journals, in particular, offer access to a wide variety of useful information at no cost. In addition, they provide avenues for publishing that are available to health care providers of all levels of training and practice. Whereas costs are less with the publishing of online open access journals, fewer resources for funding and technical support also exist. A recent rise in predatory journals, which solicit authors but charge high fees per paper published and provide low oversight, pose other challenges to ensuring the credibility of accessible scientific literature. Recognizing the value and efforts of legitimate open access online medical journals can help the reader navigate the over 11,000 open access journals that are available to date.